Research Study for Adults with Progressive MS

IRB/UVA Tracking #
Principal Investigator
J. Nicholas N Brenton
Margaret Keller
Contact Email
Contact Phone
Official Trial Title
Effect of MD1003 in progressive multiple sclerosis: a randomized double blind placebo controlled study (SPI2)
Study Description

The purpose of the study is to see if an experimental drug helps to reduces symptoms of progressive multiple sclerosis.

You may be eligible for this study if: you have been diagnosed with a progressive form of MS (getting worse, but not having relapses); you are between the ages of 18 and 65; you can walk at least 20 meters (about 66 feet)(can use a cane or walker) without resting; you have gotten worse over the past 2 years; and you are not taking Ampyra.

Study involves: taking an experimental medicine/placebo, blood draws, MRIs, questionnaires, neurological testing, physical examinations, ecg (a tracing the electrical activity of your heart), tests of thinking speed, pregnancy testing (for women of child-bearing potential), and walk assessment with a fitbit and in the clinic hallway. There are 11 clinic visits over 28 months, each visit lasting between 2 ½ and 5 hours.

Study-related exams, tests and experimental medication provided free of charge.


$50 for each completed study visit